IL-23

Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 wee